Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B1 | P15538 | 11/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 11/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.46 |
| ▸ | ACE2 | Q9BYF1 | 4/20 | 0.44 |
| ▸ | ACE | P12821 | 3/20 | 0.44 |
| ▸ | FNTA | P49354 | 4/20 | 0.43 |
| ▸ | FNTB | P49356 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3680172 | 0.88 | ACE2 (0.52) | CYP11B1CYP11B2ACE2ACEFNTA | |
| SCHEMBL3715183 | 0.88 | ACE2 (0.47) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL7382601 | 0.87 | CYP11B1 (0.47) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL7429450 | 0.87 | ACE2 (0.46) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL7391523 | 0.87 | ACE2 (0.48) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL3712455 | 0.84 | MAPT (0.47) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL1661114 | 0.84 | ACE2 (0.44) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL1655466 | 0.84 | ACE2 (0.48) | CYP11B1CYP11B2ACE2ACE | |
| SCHEMBL7379198 | 0.83 | ACE2 (0.46) | CYP19A1ACE2ACEFNTAFNTB | |
| SCHEMBL3712513 | 0.83 | ACE2 (0.45) | CYP11B1CYP11B2ACE2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2011513491-A | — | — | 2011-04-28 | — | — | JP | claimed |
| EP-2262491-A1 | THERAPY FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT | Ore Pharmaceuticals Inc. (US) | 2010-12-22 | — | — | EP | claimed |
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | claimed |
| WO-2009114516-A1 | THERAPY FOR DISORDERS OF THE PROXIMAL DIGESTIVE TRACT | ORE PHARMACEUTICALS INC. (US) | 2009-09-17 | — | — | WO | claimed |
| JP-2002543120-A | — | — | 2002-12-17 | — | — | JP | claimed |
| EP-1183019-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-03-06 | — | — | EP | claimed |
| WO-2000066104-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | claimed |
| EP-3717077-A1 | METHODS FOR MODULATING PIGMENTATION BY ANGIOTENSIN-CONVERTING ENZYME 2 MODULATION | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft (DE) | 2020-10-07 | — | — | EP | disclosed |
| WO-2010093804-A1 | ACE2 INHIBITORS FOR REDUCING GASTROINTESTINAL ADVERSE EFFECTS OF CYTOTOXIC AGENTS | ORE PHARMACEUTICALS, INC. (US) | 2010-08-19 | — | — | WO | disclosed |
| WO-2000066104-A9 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARM INC (US) | 2002-08-29 | — | — | WO | disclosed |
| WO-2002039997-A2 | ACE-2 MODULATING COMPOUNDS AND USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2002-05-23 | — | — | WO | disclosed |
| EP-1183019-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | Millennium Pharmaceuticals, Inc. (US) | 2002-03-06 | — | — | EP | disclosed |
| WO-2000066104-A2 | ACE-2 INHIBITING COMPOUNDS AND METHODS OF USE THEREOF | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2000-11-09 | — | — | WO | disclosed |